Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.LIZ HUNT
Health Editor
A drug which offers hope to thousands of people suffering from multiple sclerosis is now available on prescription in the United Kingdom.
Interferon-beta 1b has been described by doctors in the United States as the "biggest breakthrough in MS for 20 years", although British doctors are more cautious.
However, they accept that in people with the relapsing or remitting form of MS, the drug has been shown to cut the frequency of relapses by up to a third, although it does not cure of halt the disease which is a degenerative disorder of the nervous system.
The drug, to be sold as Betaferon, was at the centre of a row over rationing in the National Health Service this year, after it was claimed that it would not be available to all patients who were suitable for treatment on the grounds of cost.
A month's supply costs pounds 806 per patient - pounds 9,600 a year - and it may have to be administered over a number of years. There are around 85,000 people in the UK with MS, and up to half are potentially suitable for the drug.
The NHS Executive has issued guidelines on the prescribing of the drug and consultant neurologists in hospitals, rather than GPs, are likely to be prime prescribers at least in the short term.
A spokeswoman for Schering Health Care Ltd, which makes the drug, said yesterday: "Betaferon is expensive, but for some patients it might be eminently worth it. If people are having frequent relapses, every few months they may find they can't see or can't walk properly. This drug could make a big difference to them."
The drug has been available in the US for two years. A small number of patients in the UK have benefited from it already as it has been available for experimental use, although some health authorities have refused to pay for it.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments